BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference
call and webcast slide presentation on Thursday, May 10, at 4:30 p.m. ET to provide a corporate update and discuss financial
results for the first quarter ended March 31, 2018.
The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The
passcode for the conference call is 4857096. To access the slides and live webcast or the subsequent archived recording, visit the
"Investors & Media" section of the Ziopharm website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website
for two weeks.
About Ziopharm Oncology, Inc.
Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing
gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of
Intrexon Corporation (NYSE:XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe,
effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12
and Sleeping Beauty for genetically modifying T cells. The Company's lead asset, Ad-RTS-hIL-12 plus veledimex,
has demonstrated in clinical trials the potential to control interleukin-12, leading to an infiltration of T cells that fight brain
cancer. The Company also is advancing therapies using Sleeping Beauty, a non-viral approach to genetically modify
chimeric antigen receptor (CAR+) and T-cell receptor (TCR+) T cells, which target specific antigens in blood
cancers and neoantigens in solid tumors. Sleeping Beauty is designed using the Company's point-of-care
technology, a shortened manufacturing process which potentially can be developed as a decentralized manufacturing process based in
hospitals. These programs are being advanced in collaboration with Precigen and with MD Anderson Cancer Center, the National Cancer
Institute and Merck KGaA, Darmstadt, Germany.
Forward-Looking Disclaimer
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not
limited to, statements regarding the Company's business and strategic plans, the Company's ability to establish a
commercially-viable manufacturing approach as well as the progress and timing of the development of the Company's research and
development programs, including its potential initiation of a first in-human trial using its P-O-C manufacturing process. All such
statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control
of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking
statements. These risks and uncertainties include, but are not limited to: changes in the Company's financial condition and cash
needs, funding or other strategic opportunities that become available to the Company, the Company's ability to finance its
operations and business initiatives and obtain funding for such activities; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of other product candidates will advance further in the
preclinical research or clinical trial process and whether and when, if at all, they will receive final approval from the U.S. Food
and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T
cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the Company's other therapeutic products it develops
will be successfully marketed if approved; the strength and enforceability of the Company's intellectual property rights;
competition from other pharmaceutical and biotechnology companies; as well as other risk factors contained in the Company's
periodic and interim reports filed from time to time with the Securities and Exchange Commission, including but not limited to, the
risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal quarter
ended December 31, 2017 and subsequent reports that the Company may file with the Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the
Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances
after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Contact:
David Connolly
Ziopharm Oncology
617-502-1881
dconnolly@ziopharm.com
